REX Peptide ETF (PEPT) launches to capture the GLP-1 drug boom in one trade
As seen on the 24/7 Wall St. homepage on October 13, 2026.
- PEPTREX Peptide ETFequity0.65%
Just one new fund cleared EDGAR today: the REX Peptide ETF, an equity portfolio charging 0.65%, giving investors a single ticker on the GLP-1 era peptide drug boom instead of stock-picking it.
Continue ReadingShow less
The REX Peptide ETF became the only new fund to clear EDGAR on October 13, 2026, giving investors a single equity vehicle built around the peptide drug boom reshaping pharmaceutical investing.
The fund bundles the GLP-1 theme into one position, removing the stock-selection risk of betting on a fast-moving corner of biotechnology and pharmaceuticals.
A net expense ratio of 0.65% sits in the range typical for thematic equity ETFs, where active curation of a niche universe commands a premium over broad-market index funds.
With only one fund clearing the regulatory pipeline that day, the launch faced no competition for attention from advisors and self-directed investors seeking peptide-drug exposure without building a basket of individual names.
Mentioned: COII, MSII, NVII, TSII, CWII, HOII, LLII, PLTI, WMTI, DRNZ, ULTI, PEPT